Clinical study of Wenshen Yiqi Granules in improving airway hypersecretion in patients with chronic obstructive pulmonary disease
- Conditions
- COPD
- Registration Number
- ITMCTR2100004267
- Lead Sponsor
- The Second Affiliated Hospital of Zhejiang Chinese Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. It meets the diagnostic criteria of the Chronic Obstructive Pulmonary Disease Global Initiative 2013 Edition, and the forced expiratory volume in the first second after inhalation of bronchodilator accounts for the percentage of the predicted value (FEV1 accounts for the predicted value%) between 30% and 79%;
2. Comply with the diagnostic criteria of lung and kidney qi deficiency in the Diagnosis and Curative Effect Criteria for TCM Diseases;
3. In a stable period, no respiratory infection and acute attack of chronic obstructive pulmonary disease in the past 4 weeks;
4. Have at least 2 history of acute exacerbations or one hospitalization for acute exacerbations in the past year;
5. No other treatments were used before treatment, and no other drug clinical research was taken within one month;
6. Accept the experimental research voluntarily and sign an informed consent form. The informed consent process complies with ethical requirements.
1. Asthma or other non-chronic obstructive pulmonary diseases caused by airway obstruction;
2. Patients with severe primary diseases and mental illnesses such as cardiovascular, liver, kidney and hematopoietic system;
3. Pregnant or lactating women;
4. Those who are allergic to the study drug;
5. Those who are unwilling to accept research measures or cannot cooperate for other reasons.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MUC5AC;TNF-a;IL-8;
- Secondary Outcome Measures
Name Time Method